SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (2671)10/25/1998 11:43:00 AM
From: Bob L  Read Replies (1) of 3702
 
Well, Maurice, paddle on over to users.cts.com
if you haven't already, and look at her summary and notes on the Monoclonal Conference 98. There is quite a bit of comment on follicular cell classifications, one of the common lowgrade classifications. These comments fit with things researchers have told me. The CD20 antigen is expressed on over 90% of NHL cells. Yet Rituxan and Bexxar don't work well against aggressive NHL. Thus, something else in the cell structure is important. Unfortunately, I haven't heard exactly what it is. Or I have been too weak in cell biology to understand it when I heard it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News